Reduced intestinal-to-diffuse conversion and immunosuppressive responses underlie superiority of neoadjuvant immunochemotherapy in gastric adenocarcinoma.
Wang L, Wan L, Chen X, Gao P, Hou Y, Wu L, Liu W, Tian S, Han M, Peng S, Tan Y, Pan Y, Ren Y, Li J, Wen H, Liu Q, Zhang M, Wang T, Qin ZY, Xiang J, Chen D, Li X, Wang SN, Chen C, Li M, Li F, Wang Z, Wang B.
Wang L, et al. Among authors: wan l.
MedComm (2020). 2024 Oct 28;5(11):e762. doi: 10.1002/mco2.762. eCollection 2024 Nov.
MedComm (2020). 2024.
PMID: 39473903
Free PMC article.